181 related articles for article (PubMed ID: 31626302)
1. Tissue-Engineered Bone Tumor as a Reproducible Human in Vitro Model for Studies of Anticancer Drugs.
Sakolish C; House JS; Chramiec A; Liu Y; Chen Z; Halligan SP; Vunjak-Novakovic G; Rusyn I
Toxicol Sci; 2020 Jan; 173(1):65-76. PubMed ID: 31626302
[TBL] [Abstract][Full Text] [Related]
2. Tissue-Engineered Model of Human Osteolytic Bone Tumor.
Villasante A; Marturano-Kruik A; Robinson ST; Liu Z; Guo XE; Vunjak-Novakovic G
Tissue Eng Part C Methods; 2017 Feb; 23(2):98-107. PubMed ID: 28068876
[TBL] [Abstract][Full Text] [Related]
3. Integrated human organ-on-a-chip model for predictive studies of anti-tumor drug efficacy and cardiac safety.
Chramiec A; Teles D; Yeager K; Marturano-Kruik A; Pak J; Chen T; Hao L; Wang M; Lock R; Tavakol DN; Lee MB; Kim J; Ronaldson-Bouchard K; Vunjak-Novakovic G
Lab Chip; 2020 Nov; 20(23):4357-4372. PubMed ID: 32955072
[TBL] [Abstract][Full Text] [Related]
4. Biomechanical regulation of drug sensitivity in an engineered model of human tumor.
Marturano-Kruik A; Villasante A; Yaeger K; Ambati SR; Chramiec A; Raimondi MT; Vunjak-Novakovic G
Biomaterials; 2018 Jan; 150():150-161. PubMed ID: 29040875
[TBL] [Abstract][Full Text] [Related]
5. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
[TBL] [Abstract][Full Text] [Related]
6. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
8. Bioengineered Models of Solid Human Tumors for Cancer Research.
Marturano-Kruik A; Villasante A; Vunjak-Novakovic G
Methods Mol Biol; 2016; 1502():203-11. PubMed ID: 27115504
[TBL] [Abstract][Full Text] [Related]
9. 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization.
Molina ER; Chim LK; Salazar MC; Koons GL; Menegaz BA; Ruiz-Velasco A; Lamhamedi-Cherradi SE; Vetter AM; Satish T; Cuglievan B; Smoak MM; Scott DW; Ludwig JA; Mikos AG
ACS Biomater Sci Eng; 2020 Jan; 6(1):539-552. PubMed ID: 33463239
[TBL] [Abstract][Full Text] [Related]
10. Bioengineered Microtissue Models of the Human Bone Metastatic Microenvironment: A Novel In Vitro Theranostics Platform for Cancer Research.
Bock N
Methods Mol Biol; 2019; 2054():23-57. PubMed ID: 31482446
[TBL] [Abstract][Full Text] [Related]
11. Bioengineered human tumor within a bone niche.
Villasante A; Marturano-Kruik A; Vunjak-Novakovic G
Biomaterials; 2014 Jul; 35(22):5785-94. PubMed ID: 24746967
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
13. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the Impact of Chemotherapy on Ewing Sarcoma Cells through Combination with Cold Physical Plasma.
Nitsch A; Qarqash S; Römer S; Schoon J; Ekkernkamp A; Niethard M; Reichert JC; Wassilew GI; Tzvetkov MV; Haralambiev L
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240019
[TBL] [Abstract][Full Text] [Related]
15. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
16. Real-Time and 3D Quantification of Cancer Cell Dynamics: Exploiting a Bioengineered Human Bone Metastatic Microtissue.
Bock N; Röhl J
Methods Mol Biol; 2019; 2054():59-77. PubMed ID: 31482447
[TBL] [Abstract][Full Text] [Related]
17. 3D tissue-engineered model of Ewing's sarcoma.
Lamhamedi-Cherradi SE; Santoro M; Ramammoorthy V; Menegaz BA; Bartholomeusz G; Iles LR; Amin HM; Livingston JA; Mikos AG; Ludwig JA
Adv Drug Deliv Rev; 2014 Dec; 79-80():155-71. PubMed ID: 25109853
[TBL] [Abstract][Full Text] [Related]
18. Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity.
Sonnemann J; Kahl M; Siranjeevi PM; Blumrich A; Blümel L; Becker S; Wittig S; Winkler R; Krämer OH; Beck JF
J Cancer Res Clin Oncol; 2016 Jan; 142(1):17-26. PubMed ID: 26055805
[TBL] [Abstract][Full Text] [Related]
19. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
20. Tissue engineered models of healthy and malignant human bone marrow.
Chramiec A; Vunjak-Novakovic G
Adv Drug Deliv Rev; 2019 Feb; 140():78-92. PubMed ID: 31002835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]